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LETTER TO THE EDITOR
Haematological and molecular responses in refractory
anaemia with ring sideroblasts and thrombocytosis treated
with lenalidomide
To the Editor:
Refractory anaemia with ring sideroblasts and thrombocyto-
sis (RARS-T) is a rare entity and is deﬁned as an overlap
syndrome with clinical and morphologic features of both
myelodysplastic syndrome (MDS) and BCR-ABL-negative
myeloproliferative neoplasm, including marked thrombocyto-
sis associated with abnormal megakaryocytes (1). Mutations
in the Janus Kinase 2 gene (JAK2) and/or Splicing Factor
3B subunit 1 (SF3B1) gene have been detected in 50–70%
of patients with RARS-T (2–4). The presence of such a
mutation in either JAK2 or SF3B1 was associated with a bet-
ter overall survival in a recent European study (5).
Because of its activity in lower-risk MDS with or without
the 5q- cytogenetic abnormality (6) and in myeloﬁbrosis (7),
lenalidomide treatment has been given with success in two
patients with RARS-T. In this letter, we would like to report
a case of RARS-T that was successfully treated by lenalido-
mide.
An 84-years-old woman was referred for unexplained
normocytic anaemia (Hb 7.7 g/dL) with marked thrombocytosis
(1515 9 109/L). Peripheral blood smear showed a left shift
in neutrophils. Bone marrow cytology disclosed hypercellu-
larity (illustrated in Fig. 1A) with 15.6% erythroid cells,
77.6% granulopoietic cells, 3.2% monocytes, 4.0% lympho-
cytes, 1% blasts and numerous megakaryocytes. Ring sidero-
blasts constituted 90% of erythroid precursors (Fig. 1B).
Erythropoiesis and granulopoiesis were both hyperplasic
with evidence of dysplasia. The most prominent feature was
the presence of numerous atypical megakaryocytes of differ-
ent sizes and shapes, many with hypolobated nuclei
(Fig. 1C). Metaphase cytogenetics revealed the presence of
5q- in one mitosis, which could not be conﬁrmed by FISH
using a speciﬁc EGR1(5q31) probe, or Array-CGH analysis
(SurePrint G3 Human CGH Microarray). We could not
detect any mutation in the SF3B1 gene, but the JAK2-
V617F mutation was retrieved and estimated at 12.5–31% of
JAK2 alleles. Based on these ﬁndings, RARS-T with a
JAK2-V617F mutation was diagnosed.
Because of her anaemia, cytoreductive treatment was not
an attractive option. After transfusion of 4 units of red blood
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Figure 1 Bone marrow abnormalities before and after treatment with lenalidomide. A–C illustrates the bone marrow abnormalities at diagnosis
by applying a May–Gr€unwald–Giemsa staining on bone marrow smears. (A) Marrow cellularity was increased as a result of erythroid hyperplasia
with the evidence of dyserythropoiesis and dysgranulopoiesis. Erythroblasts resembled megaloblasts with nuclear-cytoplasmic maturation with
enlarged, lobulated nuclei. Abnormalities of granulocytes included hypogranulation and the acquired pseudo-Pelger-Hu€et nuclear abnormality. (B)
Ring sideroblasts were identified after Prussian blue stain. (C) Some megakaryocytes were dystrophic with a non-lobulated nucleus, while exces-
sive platelet clumps could be identified. D–F illustrates the improvement in myelodysplastic features after lenalidomide treatment. (D) Cellularity
in the bone marrow aspirate was normal with normal precursors in granulocytic and erythroid lineages. (E) Prussian blue staining could not
retrieve ring sideroblasts. (F) Megakaryocytes recovered their normal morphology with a nucleus containing multiple lobes and a large cytoplasm
with numerous purple granules. Pictures were taken using a Zeiss microscope with a Moticam camera (Motic Deutschland, Wetzlar, Germany)
(509 and 1009 magnification).
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cells (RBC), the patient was started on lenalidomide 10 mg
daily. Her platelet count dropped to 281 9 109/L, leuco-
cytes normalised, and she became transfusion-independent
after 4 months of treatment. After 10 months, the dysplastic
hypercellularity (Fig. 1D), atypical megakaryocytes (Fig. 1F)
and ring sideroblasts (Fig. 1E) had disappeared from the
bone marrow cytology, and the PCR for the JAK2-V617F
mutation became negative (detection limit of 2% mutated
JAK2). Lenalidomide treatment was continued, but later
stopped after 24 months because of asthenia. During the
active treatment period, the patient received only one RBC
transfusion. The patient is currently followed without active
treatment with normal platelet and leucocyte counts and a
stable macrocytic anaemia (Hb 9.4 g/dL).
Because of its low incidence, very few clinical studies have
been performed in RARS-T. The different treatment options
that were reported in a large European series included transfu-
sions and the use of erythropoietin in 50.3% and 53% of the
patients, the administration of antiplatelet drugs in 51.5% and
cytoreductive therapy in 32.2% of the cases (8).
Huls et al.(9) have recently published the efﬁcacy of sin-
gle-agent lenalidomide in two RARS-T patients. Both
patients became transfusion-independent after treatment with
lenalidomide, one of them had even a molecular response
(no detection of JAK2-V617F mutation by quantitative
PCR). More recently, lenalidomide was given to a patient
with an extensive marrow ﬁbrosis and massive splenomegaly
(10). Lenalidomide treatment was able to reduce the spleno-
megaly, but worsened the various cytopenias. The patient
described in this report is a fourth patient, who, besides
haematological response, also showed a molecular response.
These case reports indicate that lenalidomide can have
beneﬁcial effects for patients with RARS-T. However, retro-
spective studies on larger cohorts of patients and subgroup
analysis in the recent MDS005 trial (comparing lenalidomide
with placebo in MDS patients without deletion 5q) focusing
on patients with RARS-T are needed to identify the correct
place of lenalidomide in patients with RARS-T.
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